Tag Archive for: oncology

Adcendo ApS and Multitude Therapeutics Inc. Announce Global Development and Commercialization Agreement on First-in-class ADC Drug Candidate Targeting Tissue Factor

/in

August 20th, 2024, Copenhagen, Denmark and Shanghai, China — Adcendo ApS (“Adcendo”) and Multitude Therapeutics Inc. (“Multitude”) jointly announced today that they have signed a licensing agreement for the development of a novel, highly differentiated antibody-drug conjugate (ADC) targeting Tissue Factor (TF) with the development code ADCE-T02. Under this agreement, Adcendo will obtain the exclusive development and commercialization […]

Read more

iOnctura announces expansion of roginolisib clinical trial program to NSCLC

/in

• Phase II study in non-small-cell-lung-cancer (NSCLC) to be run in collaboration with the ETOP IBCSG Partners Foundation across sites in Europe • Study will investigate dostarlimab + roginolisib +/- docetaxel in patients with NSCLC resistant to first-line checkpoint inhibitor therapy Geneva, Switzerland and Amsterdam, The Netherlands, 9 July 2024 – iOnctura, a clinical-stage biopharmaceutical […]

Read more

Curve Therapeutics strengthens Leadership Team with appointment of experienced biotech executive Simon Jones

/in

Accomplished CFO and COO with proven track record in the biotech and pharmaceutical industry Strengthens Curve’s Leadership Team following £40.5 million Series A financing Southampton, UK, 9 July 2024 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening platform addressing complex and challenging disease targets, today announces the […]

Read more

Fostrox + Lenvima® holds promise of greatly improved outcomes for advanced liver cancer patients, reveals new data from Medivir at ESMO GI

/in

New results from Medivir’s Phase 1b / 2a open label trial of fostrox + Lenvima® show great promise treating second-line hepatocellular carcinoma (HCC) patients, an extremely hard to treat population Fostrox + Lenvima® achieved a 24% overall response rate (ORR) and estimated median time to progression (TTP) of 10.8 months1 (4.1 – NE) – with one […]

Read more

4SC AG: AGM highlights – Positive progress in 2023/2024 leaves company well positioned for resminostat commercialisation

/in

Planegg-Martinsried, Germany, 20 June 2024 – 4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage cutaneous T-cell lymphoma (CTCL), today publishes a summary of key highlights from its Annual General Meeting held earlier today in Martinsried, Germany. Read more…

Read more